Compare · NVO vs SYRE
NVO vs SYRE
Side-by-side comparison of Novo Nordisk A/S (NVO) and Spyre Therapeutics Inc. (SYRE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SYRE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $172.11B, about 18.6x SYRE ($9.27B).
- NVO has been more active in the news (9 items in the past 4 weeks vs 5 for SYRE).
- NVO has more recent analyst coverage (25 ratings vs 13 for SYRE).
- Company
- Novo Nordisk A/S
- Spyre Therapeutics Inc.
- Price
- -
- -
- Market cap
- $172.11B
- $9.27B
- 1M return
- -0.41%
- -
- 1Y return
- -18.26%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 9
- 5
- Recent ratings
- 25
- 13
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest SYRE
- Spyre Therapeutics to Participate in Upcoming Investor Conferences
- Spyre Therapeutics Announces Grants of Inducement Awards
- Spyre Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Spyre Therapeutics Inc.
- Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
- UBS initiated coverage on Spyre Therapeutics with a new price target
- SEC Form 8-K filed by Spyre Therapeutics Inc.
- SEC Form 424B5 filed by Spyre Therapeutics Inc.
- Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock